Introduction

Patient Case

  • The team gets a call that a 36-year-old presents with shortness of breath brought in by EMS, displaying increased work of breathing and acute distress.
  • The patient has been out of her albuterol inhaler for 7 days.
  • The provider has asthma exacerbation at the top of the differential.
  • Respiratory therapy has started albuterol and ipratropium, and the team asks whether to start steroids.
  • Should we use steroids? Which agent? What dose?

Clinical Detail

Comparison of systemic corticosteroid agents used in asthma and COPD exacerbations.

ParameterPrednisoneMethylprednisolone
(Solu-/Depo-Medrol)		Dexamethasone
(Decadron)
DosePO: 40–80 mg/day in 1–2 divided dosesIV/PO: 0.5 mg/kg q6h or 40–80 mg/day in 1–2 divided doses
IM: 120–240 mg ×1
(IV: administer over 1 min)		IV/IM/PO: 0.5–9 mg/day
FormulationOral tablet; oral solutionOral tablet; oral solution; IV; IMOral tablet; IV; IM
Time to peak / onset~2 hoursSolu-Medrol 0.5–2 hr
Depo-Medrol 6–48 hr		—
Duration12–36 hrDepo-Medrol ~15 days—

Evidence

What are the benefits of corticosteroids?

  • Asthma: increased peak expiratory flow rate (PEFR).
  • COPD: decreased duration of mechanical ventilation and NIV failure, decreased hospital length of stay, and improvement in lung function and dyspnea over the first 72 hours.

What route should be used in an asthma/COPD exacerbation?

  • Current asthma and COPD guidelines recommend low-dose oral corticosteroids for most exacerbations.
  • Oral prednisone and IV corticosteroids show no difference in the rate of lung-function improvement or length of stay; reserve IV for patients who cannot take oral.

What is the optimal duration of therapy?

  • Asthma: guidelines recommend 5–10 days of therapy.
  • COPD: a short course of no longer than 5–7 days is recommended; the REDUCE trial (Leuppi 2013) found a 5-day course non-inferior to 14 days.

How should corticosteroids be managed at discharge?

  • Oral: discharge with prednisone 40–60 mg (or equivalent) once daily for a total of 5–10 days.
  • IM: prior to discharge, a single depot dose of dexamethasone 10 mg, triamcinolone diacetate 40 mg, or methylprednisolone (Depo-Medrol) 160 mg may be given.

Recent Evidence

Leuppi 2013 (REDUCE): In acute COPD exacerbations (N=314), a 5-day course of systemic glucocorticoids was non-inferior to a conventional 14-day course for re-exacerbation within 6 months, supporting the short-course (5–7 day) guidance now reflected in GOLD 2026.

Conclusions

  • Systemic corticosteroids are indicated for both asthma and COPD exacerbations — improving PEFR in asthma and reducing mechanical ventilation, NIV failure, and hospital length of stay in COPD.
  • Oral corticosteroids are preferred; oral and IV routes show no difference in lung-function recovery or length of stay, so reserve IV for patients who cannot take oral.
  • Keep courses short: 5–10 days for asthma and no longer than 5–7 days for COPD (supported by the REDUCE trial and current GOLD guidance).
  • At discharge, send oral prednisone 40–60 mg daily for 5–10 days, or give a single IM depot dose when oral adherence is a concern.

References

  • Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved April 1, 2019, from http://www.micromedexsolutions.com/
  • Walters JA, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2018 Mar 19;3:CD006897. doi:10.1002/14651858.CD006897.pub4
  • Lazarus SC, et al. Clinical practice. Emergency treatment of asthma. N Engl J Med. 2010 Aug 19;363(8):755-64.
  • Woods JA, et al. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014 May 3;9:421-30.
  • Walls R, et al. Rosen's Emergency Medicine: Concepts and Clinical Practice. 9th ed. Philadelphia, PA: Elsevier/Saunders; 2018.
  • Niewoehner DE, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941-1947.
  • Updated guidelines & recent evidence added on review
  • Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2025 update. ginasthma.org. Summary: Venkatesan P. 2025 GINA report for asthma. Lancet Respir Med. 2025. PMID 40582369.
  • Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of COPD, 2026 report. goldcopd.org. Summary: Venkatesan P. GOLD COPD report: 2026 update. Lancet Respir Med. 2025. PMID 41317736.
  • Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223-2231. doi:10.1001/jama.2013.5023
  • Ramakrishnan S, Jeffers H, Langford-Wiley B, et al. Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care (STARR2): a randomised controlled trial. Lancet Respir Med. 2024;12(1):67-77. doi:10.1016/S2213-2600(23)00298-9
  • Soler-Cataluña JJ, Piñera P, Trigueros JA, et al. Spanish COPD Guidelines (GesEPOC) 2021 update on the diagnosis and treatment of COPD exacerbation. Arch Bronconeumol. 2022;58(2):159-170. doi:10.1016/j.arbres.2021.05.011
  • Oberle A, et al. Biologic management in severe asthma for adults: an American College of Chest Physicians clinical practice guideline. Chest. 2026;169(2):336-348. doi:10.1016/j.chest.2025.08.042
  • Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation: a pooled analysis of the BOREAS and NOTUS phase 3 trials. Lancet Respir Med. 2025;13(3):234-243. doi:10.1016/S2213-2600(24)00409-0
Tags:asthma COPD steroids corticosteroids

Source PDF

Copy of Steroids in Asthma and COPD- pharmacy friday 1.pdf